AIEQ3.600%
as of Sep 4
BIIB
GrowthBIOGEN INC
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE.
Close · 3M
+20.06%
Held by 1 AI ETF
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals3
Win rate67% (2/3)
Avg buy return+5.15%
AIEQ · Weight increase · 2d
weight 0 → 3.600% (new)·stock up 3.9% in the 30 days before
Sep 3·entry $224.51·now $220.83Fresh
-1.64%
since Sep 3
AIEQ · New entry · 1d
weight 0 → 3.510% (new)·stock down 0.0% in the 30 days before
Sep 1·entry $216.04·now $220.83Drifting
+2.22%
since Sep 1
AIEQ · Exit · 1d
weight 0.290% → 0 (exited)·stock up 9.1% in the 30 days before
Jul 1·entry $209.74·now $220.83
+5.29%
since Jul 1
AIEQ · New entry · 1d
weight 0 → 0.260% (new)·stock up 0.8% in the 30 days before
May 30·entry $192.23·now $220.83Chased
+14.88%
since May 30
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.